Proprietary Technology Platforms
Alkermes has three proprietary technologies that enable delivery of both small molecules and complex macromolecules.
Medisorb® TechnologyAlkermes’ proprietary, injectable extended-release technology, called the Medisorb® technology, enables us to develop treatments that sustain effective levels of medication in the body over a prolonged time period. We have two commercial products based on this technology, RISPERDAL® CONSTA® and VIVITROL®. Our extended-release technology allows us to encapsulate small molecules, peptides and proteins in microspheres made of biodegradable polymers. With extended-release profiles lasting from days to months, these microspheres are designed to eliminate the need for frequent dosing. Alkermes’ extended-release technology is distinguished by:
|
Medifusion™ TechnologyAlkermes’ proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, is designed to extend the circulating half-life of proteins and peptides in order to create an effective, long-acting injectable medication. The Medifusion technology is able to extend the half-life of proteins and peptides through the combined action of Fc fusion and hyperglycosylation. The resulting extended systemic half-life of the therapeutic compound allows for reduced dosing frequency. We are currently developing ALKS 6931 based on this technology. Alkermes’ Medifusion technology is distinguished by:
|
LinkeRx™ TechnologyAlkermes’ long-acting proprietary LinkeRx™ technology platform enables the creation of extended-release injectable versions of antipsychotic therapies and may also be useful in other disease areas in which long action may provide therapeutic benefits. The technology uses proprietary linker-tail chemistry to create New Molecular Entities (NMEs) derived from known agents. These NMEs are designed to have improved clinical utility, manufacturing and ease-of-use compared to other long-acting medications. We are currently developing ALKS 9070 using this technology. Alkermes’ LinkeRx technology is distinguished by:
|
Clinical Trials
-
Clinical trials are critical to the development of new medicines.
